NCT03949153View on ClinicalTrials.gov

Cryotherapy With in Situ Immunotherapy in Melanoma Metastasis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

August 16, 2019

Primary Completion Date

October 20, 2021

Study Completion Date

March 18, 2022

Conditions
Melanoma (Skin)
Interventions
DRUG

Nivolumab 10 MG/ML Intravenous Solution [OPDIVO]

Single Nivolumab 240 mg infusion at D0

PROCEDURE

Cryotherapy

Cryotherapy using interventional radiology of metastatic lymphadenopathy at D1

DRUG

Ipilimumab Injection

In situ injection with ipilimumab at D2.

Trial Locations (1)

67091

Clinique Dermatologique/Radiologie Interventionnelle/Urologie/Gynécologie-CHU de Strasbourg/ICANS, Strasbourg

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

University Hospital, Strasbourg, France

OTHER